Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity
2001; Elsevier BV; Volume: 276; Issue: 25 Linguagem: Inglês
10.1074/jbc.m010718200
ISSN1083-351X
AutoresGabriela N. Lopez, Christoph W. Turck, Fred Schaufele, Michael R. Stallcup, Peter J. Kushner,
Tópico(s)Cytokine Signaling Pathways and Interactions
ResumoPromoter-bound steroid receptors activate gene expression by recruiting members of the p160 family of coactivators. Many steroid receptors, most notably the progesterone and estrogen receptors, are regulated both by cognate hormone and independently by growth factors. Here we show that epidermal growth factor regulates the activities of the p160 GRIP1 through the extracellular signal-regulated kinase (ERK) family of mitogen-activated protein kinases. ERKs phosphorylate GRIP1 at a specific site, Ser-736, the integrity of which is required for full growth factor induction of GRIP1 transcriptional activation and coactivator function. We propose that growth factors signal to nuclear receptors in part by targeting the p160 coactivators. Promoter-bound steroid receptors activate gene expression by recruiting members of the p160 family of coactivators. Many steroid receptors, most notably the progesterone and estrogen receptors, are regulated both by cognate hormone and independently by growth factors. Here we show that epidermal growth factor regulates the activities of the p160 GRIP1 through the extracellular signal-regulated kinase (ERK) family of mitogen-activated protein kinases. ERKs phosphorylate GRIP1 at a specific site, Ser-736, the integrity of which is required for full growth factor induction of GRIP1 transcriptional activation and coactivator function. We propose that growth factors signal to nuclear receptors in part by targeting the p160 coactivators. estrogen receptor progesterone receptor ligand binding domain epidermal growth factor extracellular signal-regulated kinase mitogen-activated protein high pressure liquid chromatography green fluorescent protein mitogen-activated protein kinase/extracellular signal-regulated kinase kinase c-Jun NH2-terminal kinase glutathioneS-transferase luciferase DNA binding domain estrogen response element progesterone response element wild type transforming growth factor CREB-binding protein glucocorticoid receptor interacting protein 1 Nuclear receptors such as the estrogen receptor (ER)1 and progesterone receptor (PR) tether via their DNA binding domain to response elements in the promoter region of target genes and stimulate transcription. To do so the receptors must bind to coactivators that they recruit through transcriptional activation functions, the constitutive AF-1, found in the amino-terminal receptor domain, and the hormone-activated AF-2 in the carboxyl ligand binding domain (LBD) (for review, see Ref. 1Xu L. Glass C.K. Rosenfeld M.G. Curr. Opin. Genet. Dev. 1999; 9: 140-147Crossref PubMed Scopus (815) Google Scholar). Perhaps the most important of these coactivators is the p160 family, SRC-1 (N-CoA1), GRIP1 (TIF2/N-CoA2), and ACTR (pCIP/AIB1/RAC3). These bind to the LBD only in the presence of cognate hormone, and their binding is blocked by antagonist ligands. The mechanism of binding is now understood in atomic detail and involves the docking of coactivator nuclear receptor boxes, which have the motif LXXLL with a hydrophobic cleft that forms on the surface of the hormone-bound LBD (2Feng W. Ribeiro R.C. Wagner R.L. Nguyen H. Apriletti J.W. Fletterick R.J. Baxter J.D. Kushner P.J. West B.L. Science. 1998; 280: 1747-1749Crossref PubMed Scopus (517) Google Scholar, 3Darimont B.D. Wagner R.L. Apriletti J.W. Stallcup M.R. Kushner P.J. Baxter J.D. Fletterick R.J. Yamamoto K.R. Genes Dev. 1998; 12: 3343-3356Crossref PubMed Scopus (832) Google Scholar, 4Shiau A.K. Barstad D. Loria P.M. Cheng L. Kushner P.J. Agard D.A. Greene G.L. Cell. 1998; 95: 927-937Abstract Full Text Full Text PDF PubMed Scopus (2269) Google Scholar, 5Hong H. Darimont B.D. Ma H. Yang L. Yamamoto K.R. Stallcup M.R. J. Biol. Chem. 1999; 274: 3496-3502Abstract Full Text Full Text PDF PubMed Scopus (73) Google Scholar, 6Nolte R.T. Wisely G.B. Westin S. Cobb J.E. Lambert M.H. Kurokawa R. Rosenfeld M.G. Willson T.M. Glass C.K. Milburn M.V. Nature. 1998; 395: 137-143Crossref PubMed Scopus (1700) Google Scholar). The AF-1 domain of the estrogen, androgen, and perhaps other receptors also contacts the p160s but does so through surfaces outside of the nuclear receptor boxes (7Webb P. Nguyen P. Shinsako J. Anderson C. Feng W. Nguyen M.P. Chen D. Huang S.M. Subramanian S. McKinerney E. Katzenellenbogen B.S. Stallcup M.R. Kushner P.J. Mol. Endocrinol. 1998; 12: 1605-1618Crossref PubMed Scopus (0) Google Scholar, 8Ma H. Hong H. Huang S.M. Irvine R.A. Webb P. Kushner P.J. Coetzee G.A. Stallcup M.R. Mol. Cell. Biol. 1999; 19: 6164-6173Crossref PubMed Scopus (214) Google Scholar). The p160s are complex proteins with multiple domains (Fig. 1). In addition to the nuclear receptor boxes they have two intrinsic transcriptional activation domains AD1 and AD2, whose activities may be monitored when the coactivators are directly tethered on DNA via fusion to a heterologous DNA binding domain (8Ma H. Hong H. Huang S.M. Irvine R.A. Webb P. Kushner P.J. Coetzee G.A. Stallcup M.R. Mol. Cell. Biol. 1999; 19: 6164-6173Crossref PubMed Scopus (214) Google Scholar, 9Voegel J.J. Heine M.J. Tini M. Vivat V. Chambon P. Gronemeyer H. EMBO J. 1998; 17: 507-519Crossref PubMed Scopus (432) Google Scholar). AD1, which is essential for transcriptional mediation by p160s, is coextensive with the binding domain for the CBP/p300 family of coactivators. CBP/p300 complexes with the p160s and synergizes in coactivator function (10Kamei Y. Xu L. Heinzel T. Torchia J. Kurokawa R. Gloss B. Lin S.C. Heyman R.A. Rose D.W. Glass C.K. Rosenfeld M.G. Cell. 1996; 85: 403-414Abstract Full Text Full Text PDF PubMed Scopus (1928) Google Scholar,11Torchia J. Rose D.W. Inostroza J. Kamei Y. Westin S. Glass C.K. Rosenfeld M.G. Nature. 1997; 387: 677-684Crossref PubMed Scopus (1108) Google Scholar). In particular, CBP/p300s contain a potent acetyltransferase activity that can transfer acetate from acetyl-CoA to histones and also to other proteins in the complex on DNA (12Bannister A.J. Kouzarides T. Nature. 1996; 384: 641-643Crossref PubMed Scopus (1535) Google Scholar, 13Ogryzko V.V. Schiltz R.L. Russanova V. Howard B.H. Nakatani Y. Cell. 1996; 87: 953-959Abstract Full Text Full Text PDF PubMed Scopus (2409) Google Scholar, 14Chen H. Lin R.J. Schiltz R.L. Chakravarti D. Nash A. Nagy L. Privalsky M.L. Nakatani Y. Evans R.M. Cell. 1997; 90: 569-580Abstract Full Text Full Text PDF PubMed Scopus (1270) Google Scholar, 15Li H. Gomes P.J. Chen J.D. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 8479-8484Crossref PubMed Scopus (504) Google Scholar, 16Spencer T.E. Jenster G. Burcin M.M. Allis C.D. Zhou J. Mizzen C.A. McKenna N.J. Onate S.A. Tsai S.Y. Tsai M.J. O'Malley B.W. Nature. 1997; 389: 194-198Crossref PubMed Scopus (1070) Google Scholar, 17Imhof A. Yang X.J. Ogryzko V.V. Nakatani Y. Wolffe A.P. Ge H. Curr. Biol. 1997; 7: 689-692Abstract Full Text Full Text PDF PubMed Scopus (536) Google Scholar, 18Chen H. Lin R.J. Xie W. Wilpitz D. Evans R.M. Cell. 1999; 98: 675-686Abstract Full Text Full Text PDF PubMed Scopus (563) Google Scholar). AD2 contributes to coactivation by p160s in some circumstances and does so in part by binding CARM1 and other proteins that have histone methyltransferase activity (19Chen D. Ma H. Hong H. Koh S.S. Huang S.M. Schurter B.T. Aswad D.W. Stallcup M.R. Science. 1999; 284: 2174-2177Crossref PubMed Scopus (1006) Google Scholar). The coactivators are believed to mediate transcriptional activation by remodeling chromatin through their histone modification activities and also by direct effects on the transcriptional complex. In addition to regulating AF-2, hormones regulate steroid receptors (but not other nuclear receptors) in part by releasing the receptors from inhibitory complexes with heat shock proteins. The activity of steroid receptors is not regulated solely by hormones, however. Growth factors, such as EGF and insulin-like growth factor 1, can have profound and surprising effects on steroid receptors, even in the absence of cognate hormone (for review, see Ref. 20Weigel N.L. Zhang Y. J. Mol. Med. 1998; 76: 469-479Crossref PubMed Scopus (283) Google Scholar). In the most dramatic examples, EGF activates progesterone receptors almost as well as does hormone (21Bai W. Rowan B.G. Allgood V.E. O'Malley B.W. Weigel N.L. J. Biol. Chem. 1997; 272: 10457-10463Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar) and will partly activate ER in the absence of hormone and enhance activity in the presence of hormone (22Kato S. Kitamoto T. Masuhiro Y. Yanagisawa J. Oncology. 1998; 55 Suppl. 1: 5-10Crossref PubMed Scopus (39) Google Scholar). This later activity has been traced in part to EGF initiation of a cascade through the ERK family of MAP kinases that ultimately phosphorylates the ER at Ser-118 in the AF-1 region (23Kato S. Endoh H. Masuhiro Y. Kitamoto T. Uchiyama S. Sasaki H. Masushige S. Gotoh Y. Nishida E. Kawashima H. Metzger D. Chambon P. Science. 1995; 270: 1491-1494Crossref PubMed Scopus (1722) Google Scholar, 24Ignar-Trowbridge D.M. Pimentel M. Teng C.T. Korach K.S. McLachlan J.A. Environ. Health Perspect. 1995; 7: 35-38Google Scholar, 25Bunone G. Briand P.A. Miksicek R.J. Picard D. EMBO J. 1996; 15: 2174-2183Crossref PubMed Scopus (853) Google Scholar, 26Ignar T.D. Pimentel M. Parker M.G. McLachlan J.A. Korach K.S. Endocrinology. 1996; 137: 1735-1744Crossref PubMed Scopus (203) Google Scholar). Phosphorylation of Ser-118 leads to increased AF-1 activity by increasing binding of a p68 RNA helicase that is or becomes bound to CBP. This Ser-118-dependent link of AF-1 to CBP is in addition to the Ser-118-independent link with GRIP1 and thereby CBP (27Endoh H. Maruyama K. Masuhiro Y. Kobayashi Y. Goto M. Tai H. Yanagisawa J. Metzger D. Hashimoto S. Kato S. Mol. Cell. Biol. 1999; 19: 5363-5372Crossref PubMed Google Scholar). Although EGF-mediated phosphorylation of steroid receptors underlies part of EGF enhancement, it cannot underlie all of it. In particular, mutation of Ser-118 to glutamate in the ER AF-1 domain, while blocking phosphorylation, nonetheless preserves EGF enhancement of ER action (25Bunone G. Briand P.A. Miksicek R.J. Picard D. EMBO J. 1996; 15: 2174-2183Crossref PubMed Scopus (853) Google Scholar). Furthermore, careful mutation of sites of phosphorylation in the progesterone receptor again reveals a potent action of EGF in the absence of direct receptor phosphorylation (21Bai W. Rowan B.G. Allgood V.E. O'Malley B.W. Weigel N.L. J. Biol. Chem. 1997; 272: 10457-10463Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar). These studies suggest the existence of a pathway of EGF action that targets a nonreceptor protein. We have explored the possibility that this unknown target is one of the p160 coactivators, particularly GRIP1. We present evidence that at least part of the signal from EGF to steroid receptor is conducted through the p160 coactivators. HeLa cells were transfected by electroporation as previously described (28Webb P. Lopez G.N. Greene G.L. Baxter J.D. Kushner P.J. Mol. Endocrinol. 1992; 6: 157-167Crossref PubMed Scopus (129) Google Scholar). Generally transfections included 5 μg of luciferase reporter plasmid, 1.0 μg of Gal-GRIP expression vectors, and 1.0 μg of β-actin-β-galactosidase expression vector for internal control. After electroporation, the cells were treated with vehicle, EGF (25 ng/ml), or TGF-α (15 ng/ml). Luciferase and chloramphenicol acetyltransferase values are the means and standard deviations of triplicate treatments from a single experiment, representative of at least three independent experiments. GST-GRIP fragments were expressed in bacteria (HB101) and partially purified by glutathione-Sepharose affinity column. Beads bearing the fusion proteins (1–3 μg of total protein) were subjected to in vitro phosphorylation by activated ERK2 according to the instructions of the supplier (Stratagene, La Jolla, CA). The phosphorylated products were extracted from the beads, resolved by 10% polyacrylamide gel electrophoresis, stained with Coomassie Blue to monitor expression, and subjected to autoradiography. Approximately 8.5 μg of total protein on beads were labeled in a 50-μl final reaction volume, extracted from the beads, and purified by 10% SDS-polyacrylamide gel electrophoresis. The gel was fixed, dried, and exposed to x-ray film to visualize the radiolabeled proteins. In-gel digestion of the protein with trypsin or endoproteinase Glu-C (Roche Diagnostics, Indianapolis, IN) was carried out as described previously (29Hellman U. Wernstedt C. Gonez J. Heldin C.H. Anal. Biochem. 1995; 224: 451-455Crossref PubMed Scopus (687) Google Scholar). The resultant peptides were separated using reversed phase HPLC on a microbore C8 column (Vydac, Hesperia, CA), and the collected fractions were subjected to scintillation counting. Individual peptides were subjected to covalent Edman degradation on a Sequelon AA membrane (PerSeptive Biosystems, Cambridge, MA) with a protein sequencer (model 492; Applied Biosystems, Foster City, CA). The anilinothiazolı́noneamino acids were extracted from the filter with neat trifluoroacetic acid and scintillation counted. Radioactive profiles for each sequencing run were compared with theoretical peptide sequences derived from the protein. To construct GalDBD-GRIP1, the GalDBD coding fragment from pGBT9·GRIPFL (32Ding X.F. Anderson C.M. Ma H. Hong H. Uht R.M. Kushner P.J. Stallcup M.R. Mol. Endocrinol. 1998; 12: 302-313Crossref PubMed Google Scholar) was removed withHindIII-EcoRI and ligated toSmaI-EcoRI-cut pBS (Stratagene) giving rise to pBS·Gal4DBD. An EcoRI fragment of GRIP1 (amino acids 5–1462) from pGBT9 vector was then inserted into pBS·Gal4DBD. The entire Gal4 DBD-GRIP1 coding segment was then removed withXbaI-EcoRV and subcloned into theNheI-EcoRV site of commercially available pCMV vector (Stratagene). GalDBD-CBP has been described by Swope et al. (30Swope D.L. Mueller C.L. Chrivia J.C. J. Biol. Chem. 1996; 271: 28138-28145Abstract Full Text Full Text PDF PubMed Scopus (150) Google Scholar). GST-GRIP1–479, GST-GRIP1–766, GST-GRIP184–766 and GST-GRIP766–1462 vectors for bacterial expression have been described by Webb et al. (7Webb P. Nguyen P. Shinsako J. Anderson C. Feng W. Nguyen M.P. Chen D. Huang S.M. Subramanian S. McKinerney E. Katzenellenbogen B.S. Stallcup M.R. Kushner P.J. Mol. Endocrinol. 1998; 12: 1605-1618Crossref PubMed Scopus (0) Google Scholar). The mutants GST-GRIPS736A and GST-GRIPS554A for mammalian expression were generated by polymerase chain reaction from parental vector GST-GRIP184–766 incorporating a mutagenic primer with Pfu polymerase (QuickChange site-directed mutagenesis kit, Stratagene). MPK-1 (CL100) expression vector was a gift of D. Stokoe (Cancer Center, University of California, San Francisco). MEKK97R expression vector has been described by Mansour et al. (31Mansour S.J. Matten W.T. Hermann A.S. Candia J.M. Rong S. Fukasawa K. Vande Woude G.F. Ahn N.G. Science. 1994; 265: 966-970Crossref PubMed Scopus (1263) Google Scholar). pSG5-GRIPS736A was constructed from pSG5-GRIPFL (32Ding X.F. Anderson C.M. Ma H. Hong H. Uht R.M. Kushner P.J. Stallcup M.R. Mol. Endocrinol. 1998; 12: 302-313Crossref PubMed Google Scholar) using mutagenic primer incorporation by polymerase chain reaction as described above. Gal-GRIPS736A and Gal-GRIPS554A are derivatives of Gal-GRIPFL vector and were mutated as indicated above. All the mutants were confirmed by sequencing, and generally, functional assays of two clones were carried out. pGFP-GRIP has green fluorescent protein fused to the amino terminus of GRIP expression vector and was a gift from Yihong Wan (University of Colorado, Health Sciences Center), and pGFP-GRIPS736A was constructed by removing a 1612-nucleotide BstXI-BspEI fragment from pSG5-GRIPS736A and inserting it into theBstXI-BspEI sites of pGFP-GRIP. The point mutation was confirmed by sequencing. The pSG5ER S118A mutant is a derivative of HEO (33Tora L. Mullick A. Metzger D. Ponglikitmongkol M. Park I. Chambon P. EMBO J. 1989; 8: 1981-1986Crossref PubMed Scopus (372) Google Scholar) and is described by Webb et al. (7Webb P. Nguyen P. Shinsako J. Anderson C. Feng W. Nguyen M.P. Chen D. Huang S.M. Subramanian S. McKinerney E. Katzenellenbogen B.S. Stallcup M.R. Kushner P.J. Mol. Endocrinol. 1998; 12: 1605-1618Crossref PubMed Scopus (0) Google Scholar). GalRE-luc contains five Gal4 response elements upstream of a minimal adenovirus E1b promoter and has been previously described (34Saatcioglu F. Lopez G. West B.L. Zandi E. Feng W. Lu H. Esmaili A. Apriletti J.W. Kushner P.J. Baxter J.D. Karin M. Mol. Cell. Biol. 1997; 17: 4687-4695Crossref PubMed Scopus (38) Google Scholar). It is devoid of the pUC AP1 site as described by Webbet al. (36Webb P. Lopez G.N. Uht R.M. Kushner P.J. Mol. Endocrinol. 1995; 9: 443-456Crossref PubMed Google Scholar). ERE-luc contains the 45-mer estrogen response element from the Xenopus vitellogenin A2 promoter driving expression of the luciferase gene cloned in a pUC vector devoid of the vector AP1 site (35Lopez G. Schaufele F. Webb P. Holloway J.M. Baxter J.D. Kushner P.J. Mol. Cell. Biol. 1993; 13: 3042-3049Crossref PubMed Scopus (81) Google Scholar) and has been previously described (36Webb P. Lopez G.N. Uht R.M. Kushner P.J. Mol. Endocrinol. 1995; 9: 443-456Crossref PubMed Google Scholar). The pΔTAT3-luc reporter has three glucocorticoid response elements from the regulatory region of tyrosine aminotransferase gene placed upstream of the minimal Drosophila distal alcohol dehydrogenase promoter (−33 to +55) driving luciferase expression (37Iniguez-Lluhi J.A. Pearce D. Mol. Cell. Biol. 2000; 20: 6040-6050Crossref PubMed Scopus (179) Google Scholar). 20 million HeLa cells were transfected with 20 μg of GFP-GRIPwt or GFP-GRIPS736A expression vector, incubated overnight at 37 °C, exposed to EGF for 2 h, and harvested in lysis buffer (10 mm Hepes pH 7.9, 10 mm KCl, 0.1 mm EGTA, 0.1 mm EDTA, 20 mmβ-glycerophosphate, 0.1% Triton X-100), protease inhibitors, and Ser/Thr and Tyr phosphatase inhibitors (Sigma). The whole cell extract (50 μg) was resolved by 4–15% gradient polyacrylamide gel electrophoresis, transferred to a polyvinylidene difluoride membrane (Bio-Rad), and probed with anti-green fluorescent protein (GFP) antibodies (Convance, Berkeley, CA) or GRIP1 antibodies (Affinity BioReagents, Inc., Golden, CO) followed by the corresponding peroxidase-conjugated anti-IgG. Signals were visualized by the ECL detection kit (Amersham Pharmacia Biotech). After transfections cells to be analyzed by microscopy were distributed on cover glass-containing wells, and a duplicate group of cells was treated for regular luciferase activity. Images were collected on a Zeiss Axioplan epifluorescence microscope using a 63×, 1.35 numerical aperture oil immersion objective and fluorescein isothiocyanate excitation and emission filters (Chroma Corp., Brattleboro, VT). Digital images were collected using a Xillix CCD camera and integration times from 50 to 150 ms. All the images presented in Fig. 6 were collected at the same integration times and processed identically. A recent report suggests that growth factor stimulation of the transcriptional activation functions of CBP (38Janknecht R. Nordheim A. Biochem. Biophys. Res. Commun. 1996; 228: 831-837Crossref PubMed Scopus (173) Google Scholar, 39Liu Y.Z. Chrivia J.C. Latchman D.S. J. Biol. Chem. 1998; 273: 32400-32407Abstract Full Text Full Text PDF PubMed Scopus (87) Google Scholar) requires the domain of CBP that mediates p160 binding (10Kamei Y. Xu L. Heinzel T. Torchia J. Kurokawa R. Gloss B. Lin S.C. Heyman R.A. Rose D.W. Glass C.K. Rosenfeld M.G. Cell. 1996; 85: 403-414Abstract Full Text Full Text PDF PubMed Scopus (1928) Google Scholar). We thus examined in transfected cells whether the p160 GRIP1 tethered to a reporter gene promoter by fusion to the heterologous Gal4 DNA binding domain (Gal-GRIP1, Fig. 1) could activate transcription in response to growth factors. EGF and TGF-α had no effect on reporter gene expression in the absence of GRIP1 (Fig.1 A), but these ligands of the EGF receptor each activated transcription 5–10-fold when GRIP1 was bound to the promoter. The GRIP1 response to EGF and TGF-α required the action of the ERK family of MAP kinases because it was abolished by overexpression of the MAP kinase phosphatase CL100, by a dominant negative MEK that specifically prevents activation of ERKs, and by PD98059, a specific inhibitor of MEK activation (Fig. 1, B and C). In control experiments EGF failed to stimulate reporter gene transcription mediated by a Gal4 fusion to the herpesvirus VP16 protein, and as expected, neither PD98059 nor CL100 nor dominant negative MEK was inhibitory (data not shown). Thus GRIP1 contains an EGF-regulated transcriptional activation function, and ERKs are a component of the pathway of activation. To examine whether GRIP1 might serve as a direct substrate for ERKs, we prepared recombinant GRIP1 in Escherichia coli and incubated it with activated ERK2 in vitro. Among fragments that represent the entire protein, two fragments from amino acids 1–766 and 184–766 were strongly phosphorylated by MAP kinase (Fig. 2 A). Fragment 1–479 was unreactive, and fragment 766–1462 was barely reactive. Thus GRIP1 serves as a MAP kinase substrate in vitro, and the major site(s) of phosphorylation lies within amino acids 184–766, most likely between 480 and 766. The precise site of action of ERK MAP kinase was determined by using enzymatic protein digests and Edman analysis of the phosphate-labeled GRIP1-(184–766). Each of these digests yielded a single major labeled peptide on HPLC, and the phosphate label was on the fifth amino acid of the tryptic peptide and the ninth of the V8 peptide (Fig.2 B). Each of these assays predicts that the major site of phosphorylation of GRIP1 is serine 736 (Fig. 2 B), which is an ERK consensus site. To confirm the identity of the site, the phosphorylation reactions were repeated with wild type GRIP1-(184–766) and mutants in which Ser-736 or Ser-554, chosen because it resembles a MAP kinase site, was mutated to alanine. Phosphorylation was diminished on GRIP1 mutated on Ser-736 (Fig. 2 C). The S554A mutant was phosphorylated as efficiently as wild type. In control experiments, JNK1, a MAP kinase with different specificity, phosphorylated all three substrates equally. We concluded that Ser-736 is a major target for phosphorylation of GRIP1 by ERK but not JNK in vitro. To examine the role of Ser-736 in vivo, we repeated our studies of EGF activation of tethered GRIP1 using both wild type and mutants. EGF potentiated transcriptional activation mediated by wild type GRIP1 or the S554A mutant but was consistently weaker on the S736A mutant (Fig. 3 A, upper panel). Despite this diminution of response, the Gal-GRIPS736A mutant was well expressed as detected by Western blots (not shown) and by its ability to serve as "bait" in a mammalian two-hybrid assay (Fig. 3 A, lower panel). These results indicate that GRIP1 bound directly to the promoter requires Ser-736 for full activation by EGF. We then tested the requirement for Ser-736 when GRIP1 functions as a coactivator for the PR activated by EGF signaling. We used a reporter gene with three response elements from the tyrosine aminotransferase promoter (TAT3-luc), which the PR activates 3-fold in the presence of EGF (Fig. 3 B). Wild type GRIP1 as well as the S554A mutant potentiated PR-mediated transcription of the reporter gene approximately 4-fold after activation with EGF. Both the hormone-liganded and constitutive activity of the PR were potentiated, as is frequently observed for nuclear receptors with overexpressed coactivators (data not shown). The S736A mutant was only half as effective as wild type in potentiating PR action. In control experiments with hormone-activated glucocorticoid receptor, which does not respond to EGF, both wild type and S736A GRIP1 potentiated receptor action to similar extents (data not shown), indicating that the Ser-736 mutant of GRIP1 retains full function in some contexts. S736A GRIP1 was, however, less able than wild type GRIP1 to potentiate progestin-activated PR. Some of this deficit may reflect a role for low level activation of ERK or some other kinase on the inducible functions of GRIP1 on progestin-PR, even in the absence of deliberate EGF stimulation (data not shown). For other potential explanations see Lange et al. (40Lange C.A. Richer J.K. Shen T. Horwitz K.B. J. Biol. Chem. 1998; 273: 31308-31316Abstract Full Text Full Text PDF PubMed Scopus (167) Google Scholar). Thus S736A GRIP1 retains full ability to serve as a coactivator in some circumstances but is deficient in EGF-regulated coactivator function on the PR. Estrogen receptor activation of transcription from a reporter gene regulated by a consensus ERE is potentiated by EGF to varying extents depending on cells and culture conditions. We tested the ability of an ER S118A, mutated in the major site of EGF-dependent phosphorylation, for response to EGF with GRIP1. Without elevated GRIP1, EGF had little or no effect on transcriptional activation by ER S118A either in the absence or presence of estrogen (Fig.4 A, E2). With elevated GRIP1, EGF potentiated both unliganded and estrogen-liganded ER S118A action 2-fold. Interestingly, the S736A GRIP1 mutant was unable to support an EGF response. The isolated ER AF-2 function, which can be tested as a fusion of the ER LBD to the yeast Gal4 DNA binding domain tethered on a Gal4 response element, does not respond to EGF (Fig. 4 B). The S736A mutant was undiminished in its ability to function as a coactivator for isolated ER AF-2. Thus, S736A retains full coactivator function with the isolated ER LBD but is deficient in coactivator function for full-length ER S118A. As noted above, GRIP1 is also bound to and synergizes with CBP/p300 (10Kamei Y. Xu L. Heinzel T. Torchia J. Kurokawa R. Gloss B. Lin S.C. Heyman R.A. Rose D.W. Glass C.K. Rosenfeld M.G. Cell. 1996; 85: 403-414Abstract Full Text Full Text PDF PubMed Scopus (1928) Google Scholar, 11Torchia J. Rose D.W. Inostroza J. Kamei Y. Westin S. Glass C.K. Rosenfeld M.G. Nature. 1997; 387: 677-684Crossref PubMed Scopus (1108) Google Scholar, 41Shibata H. Spencer T.E. Onate S.A. Jenster G. Tsai S.Y. Tsai M.J. O'Malley B.W. Recent Prog. Horm. Res. 1997; 52: 141-165PubMed Google Scholar). It is possible that EGF regulates GRIP1 coactivator activities by affecting the efficiency of this interaction. Indeed, it was recently reported that activated MEK increased the association of CBP and the p160 AIB1 (42Font de Mora J. Brown M. Mol. Cell. Biol. 2000; 20: 5041-5047Crossref PubMed Scopus (402) Google Scholar). Although expression of activated MEK led to phosphorylation of AIB1 the site(s) was not analyzed. We therefore examined the ability of wild type and S736A GRIP1 to potentiate transcription mediated by CBP. We tethered CBP directly to a promoter by fusion to a heterologous Gal4 DNA binding domain. In the absence of overexpressed GRIP1 the CBP domain weakly activates transcription (Fig.5). Coexpression of wild type GRIP1 or the S554A mutant markedly potentiates transcription, which becomes sensitive to further induction by EGF. The S736A mutant of GRIP1 is, however, compromised in its ability to activate tethered CBP, and the EGF response is decreased. To confirm that the defects of the S736A mutant are not due to loss of stability or nuclear localization ability, we fused both wild type and mutant GRIP1 to GFP and monitored GRIP1 expression levels and nuclear localization. Both wild type and Ser-736 were well expressed and both localized to the nucleus (Fig. 6,top panel). Western blots indicated equal expression of wild type and mutant (Fig. 6, middle panel). When fused to GFP wild type GRIP1 had full coactivator action with tethered CBP and EGF, but the S736A mutant was diminished (Fig. 6, bottom panel). Thus the S736A mutation does not affect GRIP1 expression or localization yet has a specific effect on EGF-responsive coactivator function. The observations above indicate that EGF-activated ERK MAP kinase potentiates the transcriptional activation functions of GRIP1. Furthermore, activated ERKs phosphorylate GRIP1 on serine 736 in vitro. Mutation of Ser-736 to alanine substantially reduces the ability of GRIP1 to enhance transcription of the EGF-activated PR and of the estrogen- and EGF-potentiated ER. Because the mutant GRIP1 is fully able to function as a coactivator for the GR and for the isolated ER LBD AF-2, receptors that do not respond to EGF, it appears that the defect of S736A is limited and may indeed be specific for GRIP1 coactivator function with EGF-responsive steroid receptors or other transcription factors. In sum these observations suggest that EGF-activated ERKs increase selected coactivator functions of GRIP1 through a pathway requiring the integrity and most likely the phosphorylation of Ser-736. While this study was in preparation, it was reported that AIB1, another member of the p160 family, contained a transcriptional function that was activated by transfection with constitutive MEK, a potent activator of ERKs (42Font de Mora J. Brown M. Mol. Cell. Biol. 2000; 20: 5041-5047Crossref PubMed Scopus (402) Google Scholar). Activation by MEK was independent of the D2 domain of AIB1, suggesting that AD1 was responsible. Indeed fragments of AIB1 that contain AD1 and the nuclear receptor boxes are phosphorylated in MEK-transfected cells, suggesting that the target of MEK activation is in this region and may require AD1 for an output. Interestingly, a deletion of AD1 of GRIP1 compromises the EGF response with ER and PR (data not shown). Activation by MEK was also reported to increase the binding of CBP with AIB1 fragments that contain the AD1 domain. Our studies complement this observation in that we observed an EGF-induced increase in the functional interaction between the p160 binding domain of CBP tethered to DNA by fusion to the Gal4 DNA binding domain and GRIP1. The interaction is compromised by the Ser-736 mutation, suggesting a direct role for this site in the interaction. Sequence comparison of AIB1 and GRIP1 indicates that the Ser-736 residue is not conserved. Therefore mechanistic comparison must await the identification of the MEK-phosphorylated residues in AIB1 and their mutational analysis. The EGF pathway to GRIP1 and thence to transcription factors that recruit GRIP1 may provide a biological means to coordinate EGF effects at many different transcription factors and their target genes. It has been well established that EGF initiates a signal transduction phosphorylation cascade that leads to transcription factors such as Elk-1, ER, and PR. Direct phosphorylation of the transcription factors is required for wild type Elk-1 and ER response to EGF. Nonetheless, there are hints that in the absence of direct phosphorylation, such as when the ER Ser-118 is mutated to glutamate, an EGF response persists. Thus, we suggest that for an EGF-induced signal cascade to be fully effective the cascade may need to target both the transcription factor and the recruited coactivator. This double requirement may prevent random biological noise from activation of the EGF response. We thank Paul Webb, Branka Kovacic, and David Stokoe for plasmids and helpful discussion.
Referência(s)